InvestorsObserver
×
News Home

Analysts Expect NGM Biopharmaceuticals (NGM) Stock to Rise 132.5%; Rated Strong Buy

Monday, October 07, 2019 10:56 AM | InvestorsObserver Analysts

Mentioned in this article

Analysts Expect NGM Biopharmaceuticals (NGM) Stock to Rise 132.5%; Rated Strong Buy

NGM Biopharmaceuticals (NGM) stock is lower by -21.97% since Thursday, April 4, 2019 when NGM Biopharmaceuticals began trading. The average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives NGM stock an overall score of 48 out of a possible 100.

That score is chiefly influenced by a short-term technical score of 9. NGM's score also includes a fundamental score of 88. In addition to the average rating from Wall Street analysts, NGM stock has a mean target price of $26.67. This means analysts expect the stock to increase 132.52% over the next 12 months. There is no long-term technical score for NGM stock.

Click Here to get the full Stock Score Report on NGM Biopharmaceuticals Inc (NGM).

What's Happening with NGM Stock Today

NGM Biopharmaceuticals Inc (NGM) stock is lower by -15.37% while the S&P 500 is lower by -0.22% as of 10:49 AM on Monday, Oct 7. NGM is lower by -$2.08 from the previous closing price of $13.55 on volume of 275,760 shares. Over the past year the S&P 500 has risen 2.29% while NGM is lower by -21.97%. NGM lost -$0.01 per share in the over the last 12 months.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App